Claimable Blog

Learn about appeals, denials, and stay up to date on what is happening in the world of healthcare.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

July 1, 2026

Education

Min read

Insurance Denied Entyvio? Here's What to Do

Entyvio denials often force patients through TNF blockers before covering the gut-selective biologic their doctor chose. Here's each denial type and how to overturn it.

Your doctor prescribed Entyvio because it's the right choice for you. But then your insurer denied it.

That’s frustrating on its own, but it’s especially galling for Entyvio. The very reason gastroenterologists often choose Entyvio (your IBD needs a biologic that works in the gut without suppressing your entire immune system) is also exactly what most insurer step therapy policies ignore when they demand you try a TNF blocker first. Though there are other reasons Entyvio may be denied, this one is all too common.

Entyvio (vedolizumab) has been FDA-approved since 2014 for moderate-to-severe ulcerative colitis and Crohn’s disease. Unlike TNF inhibitors and JAK inhibitors, it targets α4β7 integrin specifically in the GI tract rather than suppressing immunity systemically.

That mechanism makes it the preferred biologic for patients with infection risks, a history of malignancy, or complications from broader immunosuppression. It’s also one of the most expensive biologics on the market (roughly $9,900 per IV infusion, approximately $3,500 per subcutaneous dose), with no biosimilar currently available. Insurers deny it often.

But denials can be overturned. Fewer than 1% of denied claims are ever appealed, according to KFF’s analysis of federal marketplace data. When patients do challenge with proper evidence, the results look very different. We see this daily at Claimable, where our appeals succeed over 80% of the time in established conditions.

Entyvio denials follow their own patterns. A UC patient denied because the insurer demands TNF failure is in a different fight than a Crohn’s patient denied during the transition from IV to subcutaneous maintenance, or one whose insurer pulled Entyvio from the formulary entirely. This guide covers each type and how to respond.

Why Listen to Us?

Claimable’s physician-led team has built thousands of appeals. Our database covers millions of clinical studies, insurer policies, and legal standards. We know which arguments overturn denials at each major insurer, and we know where their reasoning breaks down.

Why Insurance Companies Deny Entyvio Coverage

The specific reason on your denial letter determines what evidence you need, which arguments will work, what type of appeal you should submit. A generic appeal that ignores your actual denial type is unlikely to succeed, and most plans cap the number of appeals you can file.

Why Entyvio Denials Are Their Own Category

Entyvio’s gut-selective mechanism is the reason doctors prescribe it, but it’s also the reason insurers resist covering it. Most insurers still require TNF failure before they’ll approve it, forcing patients through systemically immunosuppressive drugs before granting the one designed to avoid those risks.

It comes in two formulations on two different insurance benefits. Entyvio IV is billed under the medical benefit, Entyvio SC under the pharmacy benefit. Patients who complete IV induction and transition to SC maintenance need a separate PA on the pharmacy side, creating two potential denial points for the same drug.

There is no biosimilar available yet. The first vedolizumab biosimilar application was accepted by the FDA in June 2026 (Alvotech’s AVT16, an IV-only product), with an FDA decision expected in early 2027. But Takeda’s patent runs until May 2032, so a biosimilar isn’t expected to reach patients for years.

And vedolizumab has a slower onset than some competing biologics (6-14 weeks for full response), which means some insurers pull coverage before the drug has had enough time to work.

What We See In Entyvio Appeals

Denial letters are designed to close the conversation. They shouldn’t. Here are the most common Entyvio denial types, what they actually mean, and where to focus first:
‍

Common Entyvio denial types, what the letter says, what it means, and the best first move.
Denial Type	What Your Letter Says	What It Actually Means	Best First Move
Step Therapy / TNF Failure Required	“Must try preferred alternatives first”	Insurer requires documented TNF blocker failure before Entyvio	Document prior therapy failures or request step therapy exception
Not Medically Necessary	“Does not meet medical necessity criteria”	PA submission was incomplete or lacked required severity data	Resubmit with disease activity scores and full treatment history
IV-to-SC Transition Denied	“Does not meet criteria” or separate PA required	Pharmacy benefit PA wasn’t filed or doesn’t recognize prior IV approval	Submit SC PA with documentation of successful IV induction
Continuation Denied	“Insufficient response” or “does not meet renewal criteria”	Insurer’s response timeline doesn’t match the drug’s mechanism	Document clinical trajectory and cite vedolizumab’s expected onset
Formulary Exclusion	“Not on formulary” or “non-covered product”	Plan removed Entyvio from its covered drug list	Request formulary exception with clinical necessity documentation
Site of Care Restriction	“Must use preferred infusion site”	Insurer won’t cover IV infusion at your current facility	Request exception or transition to approved site

Step Therapy and TNF Failure Required

This is the most common Entyvio denial. Most plans require documented failure on at least one TNF blocker before they’ll cover vedolizumab. Some require failure on two, or require an immunomodulator trial on top of TNF failure.

Typical step therapy requirements for vedolizumab by condition.
Condition	What Insurers Typically Require
Ulcerative Colitis	Failure on conventional therapy (5-ASAs, corticosteroids, immunomodulators). Most plans also require failure on at least one TNF blocker. Some accept vedolizumab as a first-line biologic for patients with safety concerns.
Crohn’s Disease	Failure on corticosteroids and immunomodulators. Most plans require failure on at least one TNF blocker. Some require failure on two or require a trial of ustekinumab before vedolizumab.

The argument that wins: The 2025 ACG Crohn’s disease guideline recommends vedolizumab among the advanced therapies for moderate-to-severe Crohn’s without mandating TNF failure as a prerequisite, and the 2025 ACG ulcerative colitis guideline likewise recommends vedolizumab for induction in moderate-to-severe UC. The AGA guidelines recommend vedolizumab for induction and maintenance as well. If your doctor chose vedolizumab because of a contraindication to TNF blockers (active TB, prior lymphoma, demyelinating disease, heart failure, recurrent serious infections), that is a documented medical reason, and most state step therapy exception laws are designed to cover exactly this scenario.

Not Medically Necessary

This denial is common. Sometimes it reflects a request that didn't spell out the clinical picture; other times a reviewer applied the plan's own criteria and decided your case didn't clearly meet them. Your appeal is where you make the full case either way.

What a strong resubmission includes: diagnosis with current ICD-10 codes, disease severity documented with objective measures (partial Mayo score or full Mayo score for UC, CDAI or Harvey-Bradshaw Index for Crohn’s, plus endoscopy findings if available). Include complete treatment history with dates, durations, doses, and specific reasons each prior therapy was stopped. Add a clinical rationale for why vedolizumab is the appropriate next treatment.

IV-to-SC Transition Denied

When a patient completes IV induction and their gastroenterologist prescribes the SC pen for maintenance, a new PA is required on the pharmacy side. That PA can be denied even though the patient is already approved for the same medication on the medical side.

The fix: submit the SC PA with documentation of successful IV induction and current clinical response. Frame it as continuation of established therapy, not initiation of a new treatment. If the pharmacy benefit denies it, your doctor can request that maintenance continue via IV infusion while the SC denial is appealed.

Continuation Denied

Vedolizumab’s onset of action can take 6 to 14 weeks (longer for Crohn’s). Some insurers build early response checkpoints into their criteria and pull coverage before the drug has had enough time to work.

When to push back: if you’re within the expected response window and showing any trajectory of improvement (labs trending down, symptoms improving, reduced steroid use), document that trajectory and have your gastroenterologist state that the response pattern is consistent with vedolizumab’s mechanism. The insurer’s timeline should match the drug’s pharmacology.

Formulary Exclusion

Some plans have begun removing Entyvio IV from their formularies. Document your clinical stability on vedolizumab, why alternatives are inappropriate (prior TNF failures, contraindications to JAK inhibitors), and the risk of switching a responding IBD patient to a different biologic. If your state has non-medical switching protections, reference them directly.

Site of Care Restriction

If your insurer objects to where you receive your infusion rather than whether you need it, your doctor can submit a site-of-care exception if the alternative facility can’t safely accommodate your needs. If the alternative is clinically appropriate, transitioning is often the fastest path to continued coverage.

How to Appeal an Entyvio Denial (Step by Step)

Step 1: Find Your Deadline

Your denial letter must include the reason for denial, your appeal rights, and the filing deadline. Most commercial plans allow 180 days, but UnitedHealthcare limits many plans to 65 calendar days and Medicare plans follow CMS timelines. Missing the deadline eliminates your rights regardless of how strong your case is.

Step 2: Talk to Your Doctor

Both you and your doctor have the ability to appeal. Your doctor's appeal typically focuses on the clinical appeal (resubmitting the PA, writing a letter of medical necessity, requesting peer-to-peer review). You can file your own patient-initiated appeal, and can also include personal impact, policy precedent, and legal arguments. Patient appeals work on faster timelines and include more legal rights than a provider's appeal, so if your doctor can't or won't appeal, or if their appeal gets denied, a patient appeal is a great option.

Step 3: Verify Your Documentation

Confirm that your ICD-10 codes, disease severity scores, and treatment history are complete and current, following the documentation requirements for your denial type above. For IV-to-SC denials, document successful IV induction. For continuation denials, document trending improvements.

Step 4: Get a Letter of Medical Necessity

While appeals can be approved without a LOMN, it can be helpful – ask your doctor to write you one. A strong LOMN includes your diagnosis with severity scores, complete treatment history, and clinical rationale for vedolizumab addressing the insurer’s specific denial reason. Also include any denial-specific documentation, such as TNF contraindications for step therapy denials, clinical trajectory for continuation denials, or successful IV induction for transition denials.

Step 5: Build the Appeal Package

A complete appeal includes the cover letter, the LOMN, supporting clinical records, and your personal statement. The winning structure:

Start with your story, covering the real-world impact of IBD on your daily life.

Follow with clinical evidence from the ACG 2025 and AGA guidelines supporting vedolizumab for your condition.

Close with policy and legal analysis showing how your case meets the plan’s own criteria, plus ACA protections and any applicable state step therapy exception laws.

Step 6: Submit and Track

Submit per the denial letter instructions. Insurers must respond within 30 days (standard) or 72 hours (urgent). Keep records of everything: fax confirmations, certified mail receipts, representative names.

Step 7: Escalate If Denied Again

You have the right to external review by an independent third party. Their decisions are binding on the insurer in most states. Additional options include state Department of Insurance complaints, ERISA remedies, and state step therapy exception laws.

Appeal Timelines: How Long Does an Entyvio Appeal Take?

Typical Entyvio appeal timelines by stage.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	Up to 45 days
Full process (internal + external)	6-10 weeks

The biggest factor in speed is submitting a complete package from the start. An appeal that arrives with the letter of medical necessity, clinical documentation, and personal statement can help your appeal move quicker. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Entyvio denied when my doctor specifically chose it for safety reasons?

Most insurer step therapy policies don’t account for the clinical reasoning behind a prescriber’s drug selection. They require TNF blocker failure before vedolizumab regardless of why your doctor chose it. If the reason was a safety concern with systemic immunosuppression, that’s a step therapy exception argument, and a strong one. But you have to make it explicitly in the appeal with documentation.

Can I appeal an Entyvio denial myself?

Yes. Patient appeals run on a separate legal track from your gastroenterologist’s clinical appeal, with guaranteed response timelines, the right to external review, and multiple levels of internal appeal.

Is there a biosimilar or generic version of Entyvio?

Not yet. The first vedolizumab biosimilar application was accepted by the FDA in June 2026, with an FDA decision expected in early 2027. But Takeda’s patent runs until May 2032, so a biosimilar isn’t expected to reach patients for years.

How much does Entyvio cost without insurance?

Entyvio IV runs roughly $9,900 per infusion. The SC pen costs approximately $3,500 per dose. Takeda offers financial support through EntyvioConnect, including a copay card for commercially insured patients and a patient assistance program for eligible uninsured patients.

Claimable’s physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We’re SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Biologics

Ulcerative Colitis

Crohn's Disease

Insurance Appeals

July 1, 2026

Education

Min read

Denied Insurance Coverage for Stelara? How to Appeal & Win

Stelara denials are becoming increasingly common as PBMs push patients toward biosimilars. Here's why each denial type happens and the specific strategies that overturn them.

Your doctor prescribed Stelara because it’s the right treatment for you. And if your insurer denied it, the reason often has less to do with your medical needs than with a choice made to protect their bottom line.

Since brand Stelara’s patent expired, eight ustekinumab biosimilars have received FDA approval and several have launched commercially. The major PBMs are moving aggressively toward these biosimilars, though each is doing it differently and on its own timeline. Express Scripts excluded the IV formulation in January 2026 and is pulling subcutaneous Stelara for all users by July 2026. UnitedHealth’s Optum Rx and CVS Caremark are steering members toward their own affiliated biosimilars, even where brand Stelara technically remains on the list.

The biosimilars replacing it on formularies aren’t neutral choices. Each PBM tends to prefer its own affiliated product, meaning you may have no say in which specific version of ustekinumab you’re switched to.

If you’ve been stable on Stelara, this feels like a medical decision being made for you for business reasons that you have no stake in. If you’re a new patient, the step therapy and prior authorization requirements can still block access to ustekinumab entirely, biosimilar or not.

Fewer than 1% of denied claims are ever appealed, and insurers count on that. We see this first-hand at Claimable, where our appeals succeed over 80% of the time in established conditions.

Below, we break down each denial type and the specific strategies that win each one.

Why Listen to Us?

Claimable’s physician-led team has built thousands of biologic appeals across dermatology, rheumatology, and gastroenterology and more. Our database covers millions of clinical studies, insurer policies, and legal standards. We know how to fight Stelara denials, and which arguments get results.

Why Insurance Companies Deny Stelara Coverage

The reason on your denial letter shapes your entire strategy, from the evidence you need to whether you file a formal appeal or a corrected resubmission.

Why Stelara Denials Are Their Own Category

Stelara (ustekinumab) is an IL-12/23 inhibitor approved for four conditions across two medical specialties: plaque psoriasis and psoriatic arthritis in dermatology, and Crohn’s disease and ulcerative colitis in gastroenterology. Step therapy requirements are completely different depending on your diagnosis, so two patients with identical denial language may need entirely different appeal strategies.

The biosimilar transition is the dominant factor in Stelara denials right now. With eight approved biosimilars and the major PBMs favoring their own affiliated versions (Cordavis for CVS Caremark, Nuvaila for Optum Rx, Quallent for Express Scripts/Cigna), many patients stable on brand Stelara are being pushed onto a biosimilar they didn’t choose. For many patients, that switch works fine. For some, it doesn’t, and those patients have the right to appeal.

For IBD patients, Stelara uses a weight-based IV induction dose (260 mg, 390 mg, or 520 mg depending on body weight) followed by subcutaneous maintenance every 8 to 12 weeks. This two-phase dosing structure creates a specific set of denial risks covered in the IV induction section below.

What We See In Stelara Appeals

Denial letters are written to end the conversation. Here are the most common types, what they mean, and where to start:

Common Stelara denial types, what the letter says, what it means, and the best first move.
Denial Type	What Your Letter Says	What It Actually Means	Best First Move
Formulary Removal / Biosimilar Switch	“Non-preferred product” or “must use preferred ustekinumab”	PBM removed or deprioritized brand Stelara in favor of a biosimilar	Accept biosimilar if appropriate, or document clinical reason to stay on brand
Step Therapy Required	“Must try preferred alternatives first”	Insurer requires failure on cheaper drugs before any ustekinumab	Document prior treatment history or request exception
Not Medically Necessary	“Does not meet medical necessity criteria”	PA submission was incomplete	Resubmit with disease severity scores and full treatment history
IV Induction Denied	“Does not meet criteria” or “infusion not approved”	Insurer denied the weight-based IV dose for IBD induction	Submit with correct weight-based dosing and IBD indication documentation
Dose/Interval Adjustment Denied	“Exceeds recommended dosing”	Insurer won’t cover a shortened interval (e.g., every 4-6 weeks for IBD)	Prescriber provides clinical rationale for the dose adjustment

Formulary Removal and Biosimilar Switch

More patients are hitting this denial than any other. If you’ve been stable on brand Stelara and received a letter saying it’s no longer covered or no longer preferred, you’re in the middle of the fastest biosimilar formulary transition the industry has seen.

Ustekinumab biosimilars contain the same active ingredient, meet the same efficacy and safety standards, and are held to FDA bioequivalence requirements. A subset have also been designated interchangeable with Stelara — Wezlana was the first, followed by Selarsdi and others — which allows pharmacy-level substitution. Not all biosimilars carry that designation, but interchangeability speaks to substitution rules, not to whether a biosimilar is safe or effective; the non-interchangeable products meet the same clinical standards.

If you’re stable and have no history of problems with medication transitions, switching to your plan’s preferred biosimilar may be the fastest and simplest path to continued treatment. But if you don't want to switch, you shouldn't have to just because your insurance says so.

If you’ve experienced adverse reactions during prior biologic switches, if you have documented immunogenicity concerns, or if disease stability is fragile and your doctor believes any disruption carries clinical risk, your appeal case is particularly strong. Request a formulary exception, documenting your clinical stability on brand Stelara with objective measures and explain why switching introduces risk for your specific situation. If your state has non-medical switching protections, cite them directly.

Step Therapy Required

Step therapy means your insurer requires documented failure on cheaper therapies before they’ll approve ustekinumab (brand or biosimilar). Requirements often differ substantially by diagnosis:

Typical step therapy requirements for ustekinumab by condition.
Condition	What Insurers Typically Require
Plaque Psoriasis	Topical therapy plus a conventional systemic (methotrexate, cyclosporine, acitretin) or phototherapy. Some plans also require TNF blocker failure.
Psoriatic Arthritis	Conventional DMARD (methotrexate, leflunomide, sulfasalazine). Most plans require failure on at least one TNF blocker before ustekinumab.
Crohn’s Disease	Corticosteroids and immunomodulators. Most plans require failure on at least one TNF blocker. Some require two TNF failures or a trial of vedolizumab.
Ulcerative Colitis	5-ASAs, corticosteroids, immunomodulators. Most plans require at least one TNF blocker failure.

The detail that changes outcomes: “failure” includes side effects, contraindications, and medical reasons a drug is inappropriate. Methotrexate is contraindicated in pregnancy and carries liver risk. Cyclosporine affects blood pressure and kidney function. If a required step therapy drug isn’t safe for you, document that directly.

The argument that wins: The 2025 ACG guidelines support ustekinumab as an advanced therapy for moderate-to-severe Crohn’s disease and UC without mandating TNF failure first. The AAD/NPF guidelines support IL-12/23 inhibitors for moderate-to-severe plaque psoriasis. The ACR/NPF 2018 guidelines include ustekinumab among the treatment options for active psoriatic arthritis. Citing these puts the insurer’s additional requirements in tension with professional consensus.

Not Medically Necessary

A strong appeal includes diagnosis with ICD-10 codes, disease severity with objective measures (PASI or BSA for psoriasis, tender/swollen joint counts for PsA, CDAI or partial Mayo for IBD), complete treatment history with dates and reasons each therapy was stopped, and a clear clinical rationale for ustekinumab.

IV Induction Denied (IBD Patients)

For Crohn’s disease and ulcerative colitis, Stelara requires a single weight-based IV induction infusion before transitioning to subcutaneous maintenance. The induction dose is billed under the medical benefit, while the SC injections are billed under the pharmacy benefit. This dual-benefit split creates the same denial risk that Entyvio patients face.

Denials at the induction stage can occur because the PA was submitted under the wrong benefit, because the weight-based dosing wasn’t clearly documented, or because the insurer requires additional step therapy before approving the IV component.

Confirm that the PA is filed under the medical benefit with the correct HCPCS codes and that the weight-based dose matches your current body weight.

Dose or Interval Adjustment Denied

Maintenance dosing depends on your condition. For psoriasis and psoriatic arthritis, the standard interval is every 12 weeks. For Crohn’s disease and ulcerative colitis, the labeled maintenance dose is a subcutaneous injection every 8 weeks — but some IBD patients lose response at that interval and need it shortened further, to every 4 to 6 weeks, to maintain disease control. Insurers may deny the shortened interval as exceeding recommended dosing.

The argument that wins: dose optimization for ustekinumab is supported by clinical evidence and is standard gastroenterology practice. Your appeal should include objective evidence of inadequate response at the standard interval (worsening symptoms, rising inflammatory markers, low drug levels) and your prescriber’s rationale for the adjustment.

How to Appeal a Stelara Denial (Step by Step)

Step 1: Find Your Deadline

Most commercial plans allow 180 days. UnitedHealthcare limits many plans to 65 calendar days. Medicare plans follow CMS timelines. Don't miss the deadline, or you lose your right to appeal.

Step 2: Talk to Your Doctor

Step 3: Verify Your Documentation

Confirm ICD-10 codes, disease severity measures appropriate to your condition, and treatment history with dates, doses, and reasons each therapy was stopped. For biosimilar switch appeals, document clinical stability on brand Stelara with objective metrics.

Step 4: Get a Letter of Medical Necessity

Step 5: Build the Appeal Package

A complete appeal includes the cover letter, the LMN, supporting clinical records, and your personal statement. Structure it around: your story (the real-world impact of your condition), clinical evidence (ACG, AAD/NPF, or ACR/NPF guidelines supporting ustekinumab for your diagnosis), and policy and legal analysis (how your case meets the plan’s criteria, plus ACA protections and applicable state laws).

Step 6: Submit and Track

Submit per the denial letter instructions. Insurers must respond within 30 days (standard) or 72 hours (urgent). Keep records of everything.

Step 7: Escalate If Denied Again

You have the right to external review by an independent third party. Their decisions are binding in most states. Additional options include state Department of Insurance complaints, ERISA remedies, and state step therapy or non-medical switching laws.

Appeal Timelines: How Long Does a Stelara Appeal Take?

Typical Stelara appeal timelines by stage.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	Up to 45 days
Full process (internal + external)	6-10 weeks

Complete submissions move faster. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Stelara denied if my plan used to cover it?

Since brand Stelara’s patent expired, the major PBMs have been shifting their formularies toward lower-cost biosimilars. Your plan likely still covers ustekinumab, but may now require the biosimilar version. If you need to stay on brand Stelara for clinical reasons, that requires a formulary exception with supporting documentation.

Can I appeal a Stelara denial myself?

Yes. Patient appeals run on a separate legal track from your doctor’s clinical appeal, with guaranteed response timelines, the right to external review, and multiple levels of internal appeal.

What if my insurer wants me to switch to a Stelara biosimilar?

For most patients, the switch is clinically straightforward. Ustekinumab biosimilars meet the same FDA standards as brand Stelara, and several are designated interchangeable. If you have a documented clinical reason to stay on brand (adverse reaction history, immunogenicity concerns, fragile disease stability), request a formulary exception with supporting documentation from your prescriber. Some plans may approve brand Stelara but require you to pay the cost difference.

How many Stelara biosimilars are there?

Eight ustekinumab biosimilars have been FDA-approved as of mid-2026, and several have launched commercially. The specific biosimilar your plan prefers depends on your PBM. All are approved for the same indications as brand Stelara: plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

How much does Stelara cost without insurance?

Brand Stelara’s list price is among the highest for any biologic. Biosimilars are priced significantly lower. Johnson & Johnson offers financial support through the Janssen CarePath program, and biosimilar manufacturers have their own copay and patient assistance programs. The IRA negotiated maximum fair price for Stelara in 2026 is 66% below the 2023 list price, which primarily affects Medicare Part D.

Biologics

Biosimilars

Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

June 29, 2026

Education

Min read

Insurance Denied Otezla? Here's How to Appeal and Win

Denied coverage for Otezla? Here's what each denial type really means and how to appeal it, with timelines, documentation tips, and next steps.

Otezla offers people with psoriatic disease a treatment that skips the injections, the infusions, the regular bloodwork, and the effect on the immune system that comes with biologic therapy. It's an oral pill you pick up at the pharmacy and take at home. For many people living with plaque psoriasis or psoriatic arthritis, that's exactly the kind of treatment they're looking for. Which is what makes a denial so frustrating: your doctor found a treatment that fits your life, and your insurer won't pay for it.

Otezla (apremilast) has been on the market since 2014 as the first oral PDE4 inhibitor approved for psoriatic disease. It works differently from the other targeted treatments for these conditions, which is part of why doctors reach for it when a patient can't tolerate biologics, when a biologic isn't safe for them, or when they simply do better with a daily tablet than a weekly or monthly injection.

Even so, insurers can put roadblocks in front of Otezla. Almost every plan requires what's called prior authorization, meaning your insurer won't pay until your doctor submits paperwork justifying the prescription and the plan signs off. Many plans also place Otezla in a high-cost category on their list of covered drugs (their “formulary”), which can mean a larger copay and extra requirements before they'll approve it. On top of that, Otezla is one of the most consistently denied non-biologic medications in dermatology and rheumatology.

The encouraging part is that appeals work. Fewer than 1% of denied claims are ever appealed, but a meaningful share of the ones that are get overturned. When patients come back with solid clinical evidence and the right strategy, the numbers shift in their favor. We see this every day at Claimable, where our appeals succeed over 80% of the time in established conditions.

Otezla denials don't all look alike, and that matters more than it might seem. A patient denied because they haven't tried methotrexate is in a completely different situation than one denied because the insurer wants them on a biologic first, or one denied a starter pack because the dosing schedule confused an automated system. The appeal that wins one of these would barely move the needle on another. This guide walks through each major denial type and how to push back.

Why Listen to Us?

Claimable's physician-led team builds appeals for specialty medications across dermatology, rheumatology, and gastroenterology, drawing on a database of millions of clinical studies, insurer policies, and legal standards. It's built specifically to take apart the arguments insurers use to block access to medications like Otezla. We know which tactics insurers rely on, and we know how to answer them.

Why Insurance Companies Deny Otezla Coverage

Before you respond to a denial, you need to know exactly which denial you're dealing with. The evidence you'll need, the argument most likely to succeed, and the next step you should take all depend on the specific reason your insurer gave. A generic appeal that doesn't speak to your actual denial reason wastes time and burns through your limited appeal opportunities.

What Makes Otezla Denials Different

A few things about Otezla shape how it gets denied in ways that don't apply to most medications.

It's an oral drug that's priced like a specialty one, which insurers handle awkwardly. Otezla is a daily tablet, but it costs roughly $5,000 to $6,800 per month, so plans treat it like the injectable and infused drugs that carry the heaviest restrictions, and they apply more hurdles than a typical pill prescription faces.

There's no generic version available. The FDA has approved generic apremilast applications, but patent disputes have blocked them from actually launching until approximately 2028 or 2029. Brand Otezla is the only option for now, which means a denial based on cost can't be solved by switching to a cheaper version of the same drug.

Otezla XR, the once-daily extended-release version, was approved in 2025 and is adding a new layer of confusion. Many plans haven't added Otezla XR to their list of covered drugs yet, and some require you to try standard Otezla first, even though both versions contain the same medication.

The starting schedule causes administrative problems. Otezla begins at a low dose and steps up over five days to reach the full dose on day six, dispensed in a starter pack that doesn't always fit a plan's automated limits on how much can be dispensed at once.

And step therapy rules vary by diagnosis. A patient with plaque psoriasis and a patient with psoriatic arthritis may both be denied for “step therapy required,” but the path to overturn each denial looks different.

The Most Common Otezla Denials, and What They Really Mean

Denial letters are written to sound final. They're not. Each of the most common Otezla denials points to a different first move:

Common Otezla denial types: what the letter says, what it means, and the best first move for each.
Denial Type	What Your Letter Says	What It Actually Means	Best First Move
Step Therapy Required	"Must try preferred alternatives first"	Insurer wants you to fail on cheaper treatments before Otezla	Document prior treatments you've tried, or explain why they aren't safe or appropriate for you
Not Medically Necessary	"Does not meet medical necessity criteria"	The paperwork was thin or didn't address the right points	Resubmit with disease severity details and your full treatment history
Quantity Limit / Starter Pack Issue	"Exceeds plan quantity limit" or starter pack denial	The plan's automated limits don't account for the starting schedule	Provide the FDA dosing schedule, request an override
Otezla XR Not Covered	"Non-formulary" or "must use standard Otezla"	Plan hasn't added the extended-release version, or wants you to try standard first	Request an exception with a clinical reason for once-daily dosing
Specialty Pharmacy Restriction	"Must be filled through preferred specialty pharmacy"	Plan won't cover Otezla from a regular retail pharmacy	Transfer to the required specialty pharmacy, or request an exception
Severity Threshold Not Met	"Disease severity does not meet criteria"	Insurer requires a specific severity score	Resubmit with documented severity measures from your prescriber

Step Therapy Required

This is the most common Otezla denial and the one that creates the most confusion. Step therapy means your insurer wants proof that older, cheaper treatments didn't work for you before they'll pay for Otezla, even when your doctor has already decided those treatments aren't right for you.

It gets complicated because the requirement depends on your diagnosis and on where each insurer decides Otezla belongs in the treatment order. Some plans want you to try a conventional treatment first but not a biologic. Others want you to try a biologic first. A few want both. Here's what most major insurers expect:

Typical step therapy requirements for Otezla by condition.
Condition	Typical Step Therapy Requirements
Plaque Psoriasis	A topical treatment plus a 3-month trial of an older systemic medication (methotrexate, cyclosporine, or acitretin) or light therapy. Some plans accept a prior biologic that didn't work as a substitute.
Psoriatic Arthritis	An anti-inflammatory (NSAID) plus an older DMARD such as methotrexate, sulfasalazine, or leflunomide. Some plans require a biologic DMARD before Otezla.

Here's the detail that overturns more of these appeals than anything else: “failure” doesn't only mean a drug stopped working. If a required drug caused side effects you couldn't tolerate, or isn't safe for you in the first place, that counts as failure under most plans' own rules. Methotrexate, for example, isn't safe during pregnancy and can affect the liver. If a required step therapy drug isn't safe or appropriate for you, your appeal needs to say so directly, with your doctor's reasoning to back it up.

You can also point to the medical guidelines that support Otezla for your condition. The American Academy of Dermatology and National Psoriasis Foundation recommend apremilast as an option for moderate-to-severe plaque psoriasis, and the major rheumatology guidelines recognize it for psoriatic arthritis. When your doctor's choice lines up with national guidelines, the insurer has to explain why its own internal rules don't.

One more thing worth knowing: if you've already tried and failed a biologic for psoriasis, most plans will accept that in place of stepping through the older treatments. You shouldn't have to go backward to a treatment you've already moved past.

Not Medically Necessary

This is one of the most overturned denials on appeal. Sometimes it means the original request was thin on detail; other times the insurer's reviewers applied their own criteria and decided your case didn't clearly meet them. Either way, a well-documented appeal is what turns it around.

A strong resubmission shows how serious your condition is, in concrete terms your insurer recognizes. For plaque psoriasis, that's a severity score and the percentage of your body affected. For psoriatic arthritis, it's a count of tender and swollen joints. It should also include your full treatment history, with the dates and the reason each prior treatment was stopped, plus a clear note from your doctor explaining why Otezla is the right next step for you specifically.

And if you've already been doing well on Otezla and your coverage was dropped, say so directly. If you're being moved off a treatment that's working, you can ask for a continuity of care exception, the argument that a stable patient shouldn't have effective treatment interrupted, and you can ask the plan to keep covering it while your appeal is pending so there's no gap in care.

Quantity Limit or Starter Pack Issue

Otezla starts at a low dose and steps up to the full dose over the first six days, packaged as a 27-tablet starter pack. Most plans set their dispensing limits around the standard daily dose, and the starter pack doesn't always fit neatly into those automated systems.

When you see this denial, the problem is almost always paperwork, not your eligibility for the drug. Call your doctor's office or your specialty pharmacy and ask them to resubmit with the FDA-approved starting schedule and a request to override the dispensing limit. This is one of the few Otezla denials that's usually sorted out with a phone call and a corrected request rather than a full appeal, often within a few days.

If the starter pack keeps getting denied even after that, it's time to appeal. The starting schedule is part of Otezla's official FDA instructions, not an off-label use, and a plan can't refuse to cover the dosing the drug's own label calls for. That's a strong, clean argument to put in front of a reviewer.

Otezla XR Not Covered

This denial didn't exist before 2025. Otezla XR is a once-daily tablet with the same medication and the same uses as standard Otezla, designed to make dosing easier for people who have trouble with a twice-daily schedule.

The problem is that many plans haven't added Otezla XR to their covered drug list yet, and others want you to fail on standard Otezla first before they'll approve it. That second approach is hard to defend, since it's the same medication either way.

The argument that works: request an exception and explain why once-daily dosing matters for you, including any history of missed doses or side effects that ease up with the extended-release version. If you're already doing well on Otezla XR and the plan is trying to switch you back, document that and frame it as keeping you on a treatment that's working, not starting something new.

Specialty Pharmacy Restriction

Because of how it's categorized, Otezla usually has to be filled through a specific specialty pharmacy your plan works with. If you try to fill it at your local pharmacy, you'll get a denial that has nothing to do with whether you should be on Otezla at all.

The fix is to find out which specialty pharmacy your plan requires and have your doctor send the prescription there. If that pharmacy creates a real problem, like long shipping delays or an access issue where you live, you can request permission to fill it somewhere else. In most cases, though, switching to the in-network specialty pharmacy is the fastest way to get the medication in hand.

Severity Threshold Not Met

For plaque psoriasis especially, some plans require your condition to reach a certain level of severity before they'll approve Otezla, often measured by how much of your body is affected or by a standard severity score. Some plans also count psoriasis in high-impact areas like the face, scalp, hands, feet, or genitals.

Your appeal needs updated severity documentation from your dermatologist or rheumatologist. If your psoriasis falls below the plan's threshold but affects those high-impact areas, say so directly. Plans usually recognize that psoriasis on the face, hands, feet, or genital area qualifies for systemic treatment even when the total body coverage is small, because of how much it affects daily life.

How to Appeal an Otezla Denial (Step by Step)

Appeals overturn denials more often than most patients expect. Insurance companies built their business model on the assumption that you won't fight back, and most of the time they're right, because most denied claims are never challenged. The patients who do appeal, with the right documentation and a clear strategy, see overturn rates that change the math entirely.

One thing to know before you start: your doctor's office can also file an appeal on the clinical side, and many do. It's worth asking yours directly whether they're submitting one, because it doesn't always happen automatically, and your appeal and theirs can reinforce each other. But you don't have to wait on them. The steps below walk you through filing your own.

Step 1: Read the Denial Letter and Find Your Deadline

Federal law requires your denial letter to state the specific reason for the denial, your right to appeal, and the deadline to file. Find the deadline first, because everything else depends on it.

Most commercial plans give you 180 days from the date of the denial to file an internal appeal. UnitedHealthcare is a major exception, with a 65-day window for many of its commercial plans. Medicare Advantage and Medicare Part D plans follow Medicare's own, shorter timelines. If you miss the deadline, the appeal rights you'd otherwise have effectively disappear, so move quickly.

Step 2: Confirm Your Documentation Is in Order

Before you submit, check the basics. Is your diagnosis coded correctly for your specific condition? Has your doctor documented how serious it is, in measurable terms? Are your prior treatments listed with dates and the specific reason each one was stopped?

For plaque psoriasis, that means a severity score, the percentage of your body affected, and notes on which areas are involved. For psoriatic arthritis, it means a count of tender and swollen joints and any relevant lab values. The stronger and more specific this information is, the harder the denial is to defend.

Step 3: Get a Strong Letter of Medical Necessity

The letter of medical necessity from your prescribing doctor is the centerpiece of any successful Otezla appeal. A complete letter should include your diagnosis and current severity; your full treatment history with the specific reason each prior treatment was stopped (it didn't work, the side effects were too much, it wasn't safe for you, or another clinical reason); and a clear explanation of why Otezla is the right treatment, written to answer the insurer's specific denial reason. For an Otezla XR appeal, it should explain why once-daily dosing matters for you. For a severity denial, it should describe the real-world impact even when your body-coverage number is low.

Be specific when you ask. Something like: “My Otezla was denied. Would you be willing to write a letter of medical necessity for my appeal? I can share what the insurer is looking for so we can address it directly.” Most doctors will write the letter. The hold-up is usually time, not willingness.

Step 4: Build the Appeal Package

A complete Otezla appeal includes a cover letter, the letter of medical necessity, supporting medical records, and a personal statement from you about how the denial is affecting your health and your life. Build it in three parts.

Your story. The impact of untreated or undertreated psoriatic disease isn't theoretical. Plaque psoriasis affects sleep, intimacy, work, and social life. Psoriatic arthritis can disable people in their thirties and forties. Tell the reviewer what your daily life looks like with this condition and what it would look like with effective treatment.

The clinical evidence. Point to the national guidelines that support Otezla for your diagnosis, and match them to the insurer's specific reasoning.

The policy and legal side. Show how your situation meets your plan's own coverage rules. If the denial contradicts the plan's published policy, point that out specifically. You can also cite the patient protections that apply, including your right under the Affordable Care Act to appeal and to an independent outside review, plus any state laws that limit step therapy.

Step 5: Submit and Track Everything

Submit the appeal exactly as your denial letter instructs, whether that's by fax, mail, or online portal. Your insurer has to respond within 30 days for a standard appeal, or 72 hours for an urgent appeal when a delay would seriously endanger your health.

Keep records of everything: fax confirmations, certified mail receipts, screenshots from the online portal, the names and direct numbers of anyone you speak with, and the date of every contact. If a deadline passes without a response, you have grounds to escalate.

Step 6: Escalate If the First Appeal Is Denied

A denied internal appeal isn't the end of the line. You have the right to an external review, where an independent reviewer with no financial ties to your insurer looks at your case. These reviewers focus on the medical justification for treatment, they overturn denials at meaningful rates, and in most states their decision is binding on the insurer.

Other options include filing a complaint with your state's insurance department, additional remedies under federal law if your plan comes through an employer, and state step therapy protections where they apply.

The system is designed to wear patients down, so persistence is part of the strategy. Each level of appeal brings a fresh reviewer to your case, and the patients who keep pushing are the ones who tend to get coverage.

Appeal Timelines: How Long Does an Otezla Appeal Take?

Typical timelines for each stage of an Otezla appeal.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	Up to 45 days
Full process (internal + external)	6–10 weeks

The biggest factor in how fast your appeal moves is how complete it is when you send it. An appeal that arrives with everything in one package, the letter of medical necessity, your records, and your personal statement, moves through review faster than one that triggers follow-up requests for missing documents. The average Claimable appeal gets a response in just 10 days.

FAQs

Why did my insurance deny Otezla when my doctor prescribed it?

A prescription and an approval are two separate things. Almost every plan requires prior authorization for Otezla, meaning your doctor has to submit paperwork and the insurer has to sign off before it's covered. Those requirements often include step therapy, severity thresholds, and a specific pharmacy you have to use. Your doctor made the medical decision; the insurer is applying its own coverage rules on top of it.

Can I appeal an Otezla denial myself?

Yes. As the patient, you have your own right to appeal, separate from anything your doctor's office is doing. Your appeal comes with guaranteed response times, the right to an independent outside review, and more than one level of internal review. If your doctor's prior authorization was denied, your appeal is an additional shot at coverage, not a repeat of theirs.

What if my insurer requires me to try methotrexate or cyclosporine first?

You can challenge that when the required medication isn't right for you. Methotrexate isn't safe in pregnancy and can affect the liver; cyclosporine can raise blood pressure and affect the kidneys. If your doctor has clinical reasons that a required drug isn't safe or appropriate for you, spell that out in your appeal. Many plans also accept a biologic that didn't work in place of stepping through the older drugs, so if you've already tried and stopped a biologic, your appeal can point to that.

Is there a generic version of Otezla?

Not yet. The FDA has approved generic apremilast, but patent disputes have delayed the actual launch until approximately 2028 to 2029. Until then, brand Otezla is the only option available in the United States.

What's the difference between Otezla and Otezla XR?

Both contain the same medication (apremilast) and treat the same conditions. Standard Otezla is taken twice a day after a five-day starting schedule. Otezla XR is taken once a day, with no starting schedule needed. Otezla XR was approved in 2025 and may be easier for people who struggle with twice-daily dosing, but many plans haven't added it to their covered drug lists yet.

My insurer denied my Otezla starter pack. What can I do?

This is almost always a paperwork issue rather than a medical one. The starter pack contains 27 tablets dispensed over the first five days, and automated systems sometimes flag it as more than the plan normally allows. Give your doctor's office or specialty pharmacy a call and ask them to resubmit with the FDA-approved starting schedule and a request to override the limit, which usually clears it up within a few days. If it's still denied after that, you can appeal, and the fact that the starting schedule is part of Otezla's FDA label makes for a strong argument.

How much does Otezla cost without insurance?

Otezla typically costs $5,000 to $6,800 per month without insurance. Amgen offers a copay program for people with commercial insurance that can lower out-of-pocket costs significantly, sometimes to $0 per fill, and a Bridge to Commercial Coverage program that can provide Otezla at no cost for up to 12 fills while you're waiting on prior authorization. People without commercial insurance may qualify for the Amgen Safety Net Foundation, which provides the medication at no cost to those who are eligible.

Is it worth appealing an Otezla denial?

Almost always. Left untreated, psoriatic arthritis can cause permanent joint damage, and plaque psoriasis can mean severe flares that affect work and sleep. Most denied claims are never challenged, because the process is confusing and time-consuming, but the patients who do appeal with the right documentation see overturn rates that make it well worth the effort. Your doctor prescribed Otezla because the medical case for it exists. The appeal puts that case in front of someone who actually has to evaluate it.

Claimable's physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant.

Otezla

Psoriasis

Psoriatic Arthritis

June 26, 2026

Education

Min read

Insurance Denied Xeljanz? How to Appeal and Get Covered

Denied coverage for Xeljanz? Here's what each denial type really means and how to appeal it, with timelines, documentation tips, and next steps.

If your insurer denied coverage for Xeljanz, you're not alone, and the denial is worth fighting. Your doctor prescribed Xeljanz because other treatments hadn't worked well enough for you. Being told your insurance won't cover it, after you've already tried and failed other options, is exhausting and unfair.

Xeljanz (tofacitinib) was the first oral JAK inhibitor approved in the United States. It treats rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, and for patients who can't tolerate injections and infusions or have run out of other options, it's hard to replace. It does carry an FDA boxed warning about certain serious risks, which some insurers use as a reason to add extra hurdles, even when you and your doctor have already weighed those risks together.

Here's the good news: appeals work. Fewer than 1% of denied claims are ever appealed, and insurers count on that. But patients who push back with the right documentation see real results. At Claimable, over 80% of our appeals in established conditions are approved.

Xeljanz denials come in a few different forms, and the strategy that overturns one won't always work on another. Being denied because your insurer wants more proof you failed earlier treatments is a different situation than being pushed toward generic tofacitinib, or being denied over the boxed warning. This guide walks through each type and how to respond.

Why Listen to Us?

Claimable's physician-led team builds appeals for JAK inhibitors and biologics across rheumatology and gastroenterology, drawing on a database of millions of clinical studies, insurer policies, and legal standards. We know how insurers handle tofacitinib denials, what documentation they respond to, and where the weak points in their reasoning are.

Why Insurance Companies Deny Xeljanz Coverage

The arguments that win, the evidence you'll need, and the escalation path that makes sense all come down to the specific reason your insurer gave. A generic response that doesn't address your actual denial reason can waste your limited appeal opportunities.

The Most Common Xeljanz Denials, and What They Really Mean

Denial letters are written to sound like a settled conclusion. They're not. Each of the most common denial types points to a clear first move:

Common Xeljanz denial types: what the letter says, what it means, and the best first move for each.

‍

Common Otezla denial types: what the letter says, what it means, and the best first move for each.
Denial Type	What Your Letter Says	What It Actually Means	Best First Move
Step Therapy Required	"Must try preferred alternatives first"	Insurer wants you to fail on cheaper treatments before Otezla	Document prior treatments you've tried, or explain why they aren't safe or appropriate for you
Not Medically Necessary	"Does not meet medical necessity criteria"	The paperwork was thin or didn't address the right points	Resubmit with disease severity details and your full treatment history
Quantity Limit / Starter Pack Issue	"Exceeds plan quantity limit" or starter pack denial	The plan's automated limits don't account for the starting schedule	Provide the FDA dosing schedule, request an override
Otezla XR Not Covered	"Non-formulary" or "must use standard Otezla"	Plan hasn't added the extended-release version, or wants you to try standard first	Request an exception with a clinical reason for once-daily dosing
Specialty Pharmacy Restriction	"Must be filled through preferred specialty pharmacy"	Plan won't cover Otezla from a regular retail pharmacy	Transfer to the required specialty pharmacy, or request an exception
Severity Threshold Not Met	"Disease severity does not meet criteria"	Insurer requires a specific severity score	Resubmit with documented severity measures from your prescriber

Step Therapy and TNF Failure Documentation

This is the most common Xeljanz denial, and also the most circular. The insurer's reviewers want to see your prior treatment failures documented in a particular way, and if the original request didn't include the level of detail they expect, you can get denied even though you've already met the requirement.

What insurers typically require to document prior treatment failure for Xeljanz:

Typical step therapy requirements for Otezla by condition.
Condition	Typical Step Therapy Requirements
Plaque Psoriasis	A topical treatment plus a 3-month trial of an older systemic medication (methotrexate, cyclosporine, or acitretin) or light therapy. Some plans accept a prior biologic that didn't work as a substitute.
Psoriatic Arthritis	An anti-inflammatory (NSAID) plus an older DMARD such as methotrexate, sulfasalazine, or leflunomide. Some plans require a biologic DMARD before Otezla.

Here's the detail that matters most: a prior treatment “failure” has to be documented with specifics, not just stated. That means the dates you were on each treatment, how long, the dose, and the specific reason it was stopped (it didn't work at the right dose, the side effects were too much, or it wasn't safe for you). A request that just says “patient failed Humira,” with no dates, dose, or reason, is the most predictable way to land this denial.

You can also point to the national guidelines that support tofacitinib for your condition. For rheumatoid arthritis, the 2021 American College of Rheumatology guidelines recommend adding a biologic or a JAK inhibitor like Xeljanz when methotrexate alone isn't enough. For ulcerative colitis, the 2025 American College of Gastroenterology guidelines recommend JAK inhibitors including tofacitinib for moderate-to-severe disease. When your doctor's choice lines up with national guidelines, the insurer has to justify why its own rules don't.

Not Medically Necessary

A “not medically necessary” denial is one of the most common ones we see, and one of the most worth challenging. Sometimes it reflects a request that didn't spell out the clinical picture; other times a reviewer applied the plan's own criteria and decided your case didn't clearly meet them. Your appeal is where you make the full case either way.

Your appeal is where you make that case in full. The strongest ones include your diagnosis with current codes; a measure of how active your disease is, using the standard scores doctors use for your condition; a complete treatment history with dates, doses, and the reason each prior treatment was stopped; and a clear explanation connecting how serious your condition is and what you've already tried to why Xeljanz is the right choice. And if you've already been on Xeljanz and it's been working, say so plainly. Many plans' own rules approve continued coverage when a patient is stable or improving on a treatment, so showing that you've gotten better and stayed better on Xeljanz can meet the insurer's standard directly. Laid out that way, a denial that called your treatment “not medically necessary” becomes much harder for the insurer to defend.

Safety-Based or JAK Class Restriction

This denial didn't exist before 2021. After the ORAL Surveillance trial, the FDA required a boxed warning on all JAK inhibitors (Xeljanz, Rinvoq, Olumiant) about increased risks of serious heart problems, cancer, blood clots, and death. Some insurers responded by adding safety requirements of their own: asking for a heart-risk assessment, limiting approval to patients under a certain age, or restricting coverage based on specific risk factors.

Sometimes the requirement is reasonable. The trial found real risks, especially for rheumatoid arthritis patients over 50 who have at least one heart-disease risk factor. If your insurer wants documentation that your doctor weighed your heart risk and decided the benefit is worth it, that's usually something your doctor can provide from your chart.

Other times it's worth pushing back. If the insurer is applying a blanket JAK restriction that goes further than the FDA label requires, or denying Xeljanz for a group the trial didn't actually study (younger patients, patients without heart-risk factors, or ulcerative colitis patients, since the trial was done in RA patients), your appeal should point that out. The FDA didn't pull Xeljanz from the market. It added a warning and narrowed who it's labeled for. If you fit the labeled use and your doctor has weighed the risks, the insurer's extra restrictions need their own medical justification.

Generic Substitution Required

This denial type is emerging in 2026 as generic tofacitinib reaches the market. Generic immediate-release tofacitinib (5 mg and 10 mg) received FDA approval in 2025, and broader availability is expected through 2026. Some plans are now requiring patients to use generic tofacitinib before they'll cover brand Xeljanz.

Sometimes the switch is straightforward. If you're on immediate-release Xeljanz and your plan now offers generic tofacitinib at a lower tier or copay, switching may work just as well for you and cost less. Generic drugs contain the same active ingredient at the same dose and meet the same FDA standards for how the drug behaves in your body.

When it's worth appealing: if you've been stable on brand Xeljanz and have a clinical reason to stay on it (a specific tolerability profile, a bad experience with a generic version before, or concerns about switching a controlled autoimmune condition to a new manufacturer), document those reasons and request an exception. And if you're on Xeljanz XR and the plan is requiring generic immediate-release as a substitute, that's a different formulation with a different dosing schedule, not a direct generic swap.

Xeljanz XR Not Covered

Some plans cover immediate-release tofacitinib but haven't added Xeljanz XR (taken once daily) to their covered drug lists, or they require a trial of twice-daily dosing before approving the extended-release version.

The argument that works: if once-daily dosing improves your ability to stay on schedule, reduces side effects (some patients tolerate XR better because of how the drug is released), or fits your routine in a way the twice-daily version doesn't, those are clinical reasons that support an exception. If you're already stable on Xeljanz XR, frame the appeal around staying on a treatment that's working rather than starting something new.

Worth knowing: a generic version of Xeljanz XR isn't widely available yet, so this denial may stick around even as generic immediate-release tofacitinib enters the market.

Diagnosis Not Covered or Off-Label

Occasionally a denial traces back to a mismatch between the diagnosis codes that were submitted and the insurer's approved uses for tofacitinib. This can happen when billing codes are outdated, when the request doesn't specify the exact condition, or, in rare cases, when the drug is being used for something that isn't in the FDA-approved label.

The fix is to verify that your diagnosis codes are current and that the request clearly connects your condition to one of the five FDA-approved uses of tofacitinib. If it's a coding error, ask your doctor's office to correct it and resubmit, which usually takes care of it.

How to Appeal a Xeljanz Denial (Step by Step)

Most patients never challenge a denied claim, and insurers have built their coverage model around that. The patients who do fight back, with clear evidence and a structured approach, see overturn rates that should give everyone else pause about walking away from a denial.

One thing to know before you start: your doctor's office can also appeal on the clinical side, and many do. It's worth asking yours directly whether they're submitting one, since it doesn't always happen automatically, and your appeal and theirs can reinforce each other. But you don't have to wait on them. The steps below walk you through filing your own.

Step 1: Identify Your Deadline

Your denial letter has to state the specific reason for the denial, your right to appeal, and the deadline to file. Find the deadline immediately. Most commercial plans allow 180 days, but UnitedHealthcare limits many of its commercial plans to 65 days, and Medicare Part D plans follow Medicare's own timelines. A strong case filed even one day late has no standing, so treat the deadline as your first task.

Step 2: Verify Your Documentation

Before you put the appeal together, confirm the basics. Are your diagnosis codes correct for your condition? Is your prior treatment history documented with dates, doses, durations, and the reason each was stopped? For Xeljanz specifically, if your plan requires a heart-risk assessment, is that in your records?

Make sure your doctor has documented how active your disease is, using the standard measures for your condition. The appeal is only as strong as the medical record behind it.

Step 3: Get a Letter of Medical Necessity

The letter of medical necessity is the foundation of the appeal. For Xeljanz, it should include your diagnosis and current disease activity; your full treatment history with what happened on each prior treatment and why it was stopped; and a clear explanation of why tofacitinib is the right choice, written to answer the insurer's specific denial reason. If the denial was safety-based, the letter should include your doctor's assessment of your heart and other risks and why the benefit outweighs them for you. If it was about using the generic, the letter should explain why brand Xeljanz or the XR version is medically necessary for you.

Be direct when you ask. Something like: “My Xeljanz was denied and I need a letter of medical necessity for the appeal. I can share exactly what the insurer is asking for so we can address it.” Most doctors are willing. The hold-up is usually time, not intent.

Step 4: Assemble the Appeal

A complete appeal brings together four things: a cover letter, the letter of medical necessity, supporting medical records (labs, imaging, scope reports, disease-activity assessments), and a personal statement from you about how the denial affects your daily life. Build it in three parts.

Your story. What does your condition look like day to day without good treatment? Rheumatoid arthritis that keeps you from opening jars or climbing stairs. Ulcerative colitis flares that keep you home. Psoriatic arthritis that makes it hard to work with your hands. Ankylosing spondylitis pain that wakes you at 3 AM. The reviewer reads dozens of cases; your statement is what turns a file into a person.

The clinical evidence. Point to the national guidelines that support tofacitinib for your condition, and match them to the insurer's stated reason for the denial.

The policy and legal side. Show that your situation meets the plan's own published rules. If the denial contradicts that policy, or ignores records you already sent, point it out specifically. You can also cite your right under the Affordable Care Act to appeal and to an independent outside review, plus any state step therapy laws that apply.

Step 5: Submit and Track

Follow the submission instructions in your denial letter exactly. Your insurer has to respond within 30 days for a standard appeal, or 72 hours for an urgent one when a delay would seriously endanger your health. If you're in an active flare or your disease is progressing fast, an urgent appeal may be the right route.

Document every contact. Save fax confirmations, certified mail receipts, portal screenshots, and the names of anyone you speak with. If the insurer misses its deadline, that's grounds to escalate.

Step 6: Escalate If Denied Again

If your internal appeal is denied, you have the right to an external review by an independent reviewer who isn't connected to your insurer. They look at the medical merits of your case, and in most states their decision is binding on the insurer. For a JAK inhibitor denial, an outside reviewer may be more open to the careful risk-versus-benefit judgment your insurer's automated system missed.

Each level of escalation puts your case in front of someone new. The patients who push past the first denial are the ones who tend to get coverage.

Appeal Timelines: How Long Does a Xeljanz Appeal Take?

Typical timelines for each stage of a Xeljanz appeal.

Typical timelines for each stage of an Otezla appeal.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	Up to 45 days
Full process (internal + external)	6–10 weeks

Complete submissions move faster. An appeal that arrives with the letter of medical necessity, your records, and your personal statement all in one package avoids having to resubmit with more complete documentation. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Xeljanz denied when my doctor already tried other treatments first?

Because the insurer's step therapy requirements are separate from the FDA's prescribing rules. Even though the FDA label limits Xeljanz to patients who've failed prior treatments, your insurer has its own standards for what counts as an adequate trial, and the original request may not have included the level of detail the reviewer expected. The denial often reflects a documentation gap, not a real clinical disagreement.

Can I appeal a Xeljanz denial myself?

Yes. As the patient, you have your own right to appeal, separate from what your doctor's office handles on the clinical side, with its own protections: guaranteed response times, the right to an independent outside review, and more than one level of internal review. If your doctor's prior authorization was denied, your appeal is an independent chance to make the case.

Is Xeljanz safe? I heard about the boxed warning.

Xeljanz carries an FDA boxed warning based on the ORAL Surveillance trial, which found increased risks of heart problems, cancer, blood clots, and death compared to TNF inhibitors in rheumatoid arthritis patients over 50 with at least one heart-disease risk factor. The risks are real and should be part of the conversation between you and your doctor. That said, the FDA kept Xeljanz on the market because it remains an appropriate treatment for patients who've failed other options, as long as the risks are weighed against the benefits in each case. A blanket insurer denial isn't the same as a personal risk assessment by your physician.

Is there a generic version of Xeljanz?

Generic immediate-release tofacitinib (5 mg and 10 mg tablets) received FDA approval in 2025, and broader availability is expected throughout 2026. A generic version of Xeljanz XR (extended-release) isn't widely available yet. Even with generics entering the market, most plans are still expected to require prior authorization. If your plan is pushing you toward generic tofacitinib and you have a clinical reason to stay on brand Xeljanz, that can be appealed.

What's the difference between Xeljanz and Xeljanz XR?

Both contain tofacitinib. Xeljanz is the immediate-release version, taken twice a day. Xeljanz XR is the extended-release version, taken once a day. They treat the same conditions. Some patients tolerate XR better because of how gradually the drug is released, and once-daily dosing can make it easier to stay on schedule. Not all plans cover both versions, and generics are currently available only for the immediate-release tablets.

How much does Xeljanz cost without insurance?

Brand Xeljanz runs roughly $6,000 to $9,000 per month at retail, depending on the version and pharmacy. Pfizer offers a copay savings card for people with commercial insurance, a free trial voucher, and a patient assistance program for eligible uninsured or government-underinsured patients through XELSOURCE (1-844-935-5269). As generic tofacitinib becomes more available, pricing may shift, but specialty placement and prior authorization requirements are expected to remain.

Is it worth appealing a Xeljanz denial?

For most patients, yes. Xeljanz is usually prescribed after other options have already failed, which means there aren't many alternatives left. Interruptions in treatment for autoimmune conditions can trigger rheumatoid arthritis flares that speed up joint damage, ulcerative colitis episodes that can lead to hospitalization, and disease that gets harder to control the longer it goes untreated. This is exactly what the appeals process is for. A utilization system made a coverage decision that doesn't match your medical situation, and your doctor prescribed Xeljanz because the evidence supports it for you. The appeal puts that evidence in front of a reviewer who has to evaluate it on the merits.

Claimable's physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Start your appeal today.

Xeljanz

Rheumatoid Arthritis

Ulcerative Colitis

JAK Inhibitors

June 19, 2026

Education

Min read

Insurance Won't Cover Ozempic? Here's What to Do

Did your insurance provider deny coverage for Ozempic? Here's why it was denied and how to fight back with an appeal that actually wins.

Ozempic is one of the most broadly covered GLP-1 medications on the market. Novo Nordisk’s data shows that the vast majority of insured patients have plans that list Ozempic on their formulary.

But “covered” is doing a lot of heavy lifting in that number, because it includes plans that bury Ozempic behind prior authorization requirements, step therapy mandates, and documentation thresholds that block access at the pharmacy counter. The result is a medication your plan technically covers but that the system’s own bureaucracy keeps out of your hands. And if your prescription was written off-label for weight loss rather than type 2 diabetes, most insurers won’t even consider it.

What insurers don’t expect is for you to do something about it. Fewer than 1% of denied claims ever get appealed, a number that saves the insurance industry billions annually. That statistic reflects how confusing the appeals process is, not how hopeless it is. When patients challenge denials with the right evidence, overturn rates are dramatically higher. At Claimable, we see this constantly: our appeals succeed over 80% of the time in established conditions.

Winning an Ozempic appeal starts with identifying the specific type of denial you received, because the strategy for overturning a step therapy requirement is very different from the strategy for fixing a coding error or challenging a medical necessity rejection.

Why Listen to Us?

Claimable’s physician-led team has handled thousands of GLP-1 appeals. Our work draws on millions of clinical studies, insurer policies, and legal standards, built specifically to dismantle the arguments insurers use to block access to medications like Ozempic. Insurers increasingly use AI and automation to deny claims in minutes. Claimable turns that same technology around and puts it to work for patients. We know which tactics each insurer relies on, and we know how to beat them.

Why Insurance Companies Deny Ozempic Coverage

Before building your appeal, understand the specific reason that your insurance denied coverage. Understanding your denial type means that you can fight it with the correct arguments.

What We See Across Thousands of GLP-1 Appeals

Denial letters use insurer language engineered to sound final, even though most denials are anything but. Here’s how to decode the most common denial types for Ozempic, what they actually signal about your situation, and where to begin:

Typical timelines for each stage of an Ozempic insurance appeal.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	45–60 days
Full process (internal + external)	6–10 weeks

Off-Label Use Denials: The Weight Loss Problem

This is the denial type unique to Ozempic. It is not FDA-approved for weight loss, which is Wegovy’s indication, even though both drugs contain semaglutide. Ozempic is approved for type 2 diabetes, and for cardiovascular and kidney risk reduction in adults who have type 2 diabetes. When it’s prescribed purely for weight management in someone who doesn’t have one of those approved indications, most insurers will deny it outright, and that denial is difficult to overturn because it’s technically correct.

Your options: If you have type 2 diabetes, the issue may be a coding error rather than a true coverage dispute (see Step 0 below). If you don’t have an approved indication and are seeking semaglutide for weight management, consider asking your doctor about Wegovy, the version of semaglutide that carries an FDA-approved weight management indication. If your prescriber believes off-label Ozempic is clinically appropriate, some plans will consider a formulary exception with a strong letter of medical necessity, though this is a harder fight.

Step Therapy Denials

Step therapy requires you to prove that cheaper medications failed before the insurer will approve Ozempic. That typically means documented trial and failure of metformin, and sometimes a second-line oral agent like a sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor.

The detail most patients miss: “failure” has a broad medical definition that works in your favor. Intolerable side effects, contraindications based on your medical history (even if you never took a dose), and inadequate glycemic control all qualify. If alternatives are clinically inappropriate, your doctor can request a step therapy exception, and this argument is strongest if you have cardiovascular disease or chronic kidney disease given Ozempic’s specific indications for both. If metformin is medically appropriate and you haven’t tried it, completing step therapy is sometimes the fastest route to approval.

Not Medically Necessary Denials

This denial rarely reflects a careful clinical review. It usually means the PA submission lacked documentation, and it’s one of the most commonly overturned denial types on appeal.

What a strong submission requires: your current A1C, a documented history of diabetes management attempts, comorbidities (cardiovascular disease, chronic kidney disease, obesity, hypertension, and dyslipidemia are all relevant), prior medications tried and outcomes, relevant lab work, and a clear rationale for why Ozempic specifically is the appropriate treatment. If your initial submission was sparse, a resubmission with thorough documentation can change everything.

Not on Formulary Denials

Every plan maintains a list of preferred medications, and yours may not include Ozempic. This is typically a business decision driven by rebate agreements, not a clinical judgment about what’s best for you.

How to respond: Request a formulary exception. Every insurer is required to have one for non-formulary drugs that are medically necessary. Your case is strongest if formulary alternatives have failed, caused side effects, or are contraindicated. If the insurer prefers a different GLP-1, document your clinical response to Ozempic and any cardiovascular or kidney disease history that makes its specific indications relevant.

PA Requirements Not Met

This denial means the insurer says you didn’t satisfy one or more specific criteria, such as an A1C threshold, documented metformin use, lifestyle modifications, or comorbidity documentation. It doesn’t always mean you actually fail those criteria. Insurers sometimes misapply their own rules or overlook submitted documentation. Review each criterion against your records and address gaps directly in your appeal.

Quantity Limit Denials

If your prescriber wrote for a dose or quantity that exceeds your plan’s default limits, your prescriber should submit a quantity or dose override request with documentation showing why the prescribed amount is medically appropriate.

How to Appeal an Ozempic Denial: Step by Step

A denial is an opening position. The appeals process exists specifically because initial coverage decisions are frequently wrong.

Step 0: Confirm Your Prescription is Coded Correctly

Before you build an appeal, check whether the denial is actually a coding problem. Ozempic denials are frequently triggered by a mismatch between the diagnosis code on the prescription and the drug’s FDA-approved indications.

If your prescriber submitted a general or vague code instead of a specific type 2 diabetes code (E11 and its subcategories), or if the prescription was coded for weight management in a patient without diabetes, the insurer may have auto-denied the claim without clinical review.

Work with your prescriber’s office to verify the ICD-10 code that was submitted. If it was wrong or incomplete, a corrected prior authorization resubmission may resolve the denial.

Step 1: Read Your Denial Letter Carefully

Your denial letter is required by law to include the specific reason for denial, your appeal rights, and the deadline to file.

Find your deadline first. Most commercial plans allow 180 days, but there are important exceptions: UnitedHealthcare allows just 65 days for many plan types, and Medicare Advantage plans follow CMS guidelines of 60 days. Missing the deadline eliminates your right to appeal entirely, so identify it immediately.

Step 2: Know That You Have Your Own Appeal Rights On Top of Your Doctor’s

Your provider can and should appeal on the clinical side. But you also have the right to file your own appeal as the patient, and it runs on a separate track with its own legal protections.

Why this matters: Patient-initiated appeals carry guaranteed response timelines, external review rights, and multiple appeal levels that provider-level appeals may not offer. Use both tracks simultaneously.

Use both tracks: Your doctor makes the clinical case while you exercise your independent rights. If your prescriber’s prior authorization was denied, that doesn’t close the door on your side of the process.

Step 3: Get a Letter of Medical Necessity

A letter of medical necessity (LOMN) from your prescribing physician is the single most important document in your appeal package.

What a strong LOMN for Ozempic should include: your diagnosis codes (E11.x for type 2 diabetes, plus relevant comorbidity codes), current and historical A1C levels, documented comorbidities with particular emphasis on cardiovascular disease and chronic kidney disease given Ozempic’s expanded indications, a summary of prior treatments tried and why each was insufficient or inappropriate, supporting clinical evidence from the SUSTAIN trials for glycemic control, SUSTAIN 6 for cardiovascular outcomes, or FLOW for kidney outcomes depending on your situation, and a clear explanation of why Ozempic, rather than an alternative GLP-1 or diabetes medication, is the clinically appropriate choice.

How to ask: Be direct with your doctor. “My insurance denied Ozempic. Would you be willing to write a letter of medical necessity for my appeal? I can provide information on what the insurer typically looks for.” If your doctor’s office hasn’t written many of these, offering to share a template can improve the quality and completeness of the letter. You can download our LOMN template here and forward it to your provider.

Step 4: Build Your Appeal Package

Your submission should include a cover letter summarizing your case, the letter of medical necessity, supporting clinical documentation (A1C history, lab results, visit notes, cardiovascular or kidney function data if relevant), and a personal statement explaining how the denial has affected your health and daily life.

A winning appeal weaves together three elements:

Your story: How your condition affects your ability to work, manage daily responsibilities, and maintain your health. Reviewers are people, and context matters.

Clinical evidence: The SUSTAIN trial program for glycemic control (A1C reductions of 1.0% to 1.8% across 8,000+ patients), SUSTAIN 6 for cardiovascular risk reduction (26% reduction in MACE), or FLOW for kidney disease progression (24% risk reduction). Match the evidence to your situation.

Policy and legal analysis: How your situation meets your plan’s own coverage criteria, relevant state insurance laws, and federal protections under the ACA. If the denial contradicts the insurer’s published medical policy, call it out specifically.

Step 5: Submit and Track

Submit to your insurer per the instructions in your denial letter. They’re required to respond within 30 days for standard appeals (72 hours for urgent appeals).

Keep records: Document when you submitted, how (fax, mail, portal), confirmation numbers, and the name of anyone you speak with. Documents go missing in insurer systems more often than you’d expect, and a clear paper trail protects your appeal.

Step 6: Escalate If Needed

A denied internal appeal isn’t the final answer. You have the right to request an external review by an independent reviewer with no relationship to the insurer. External reviewers evaluate clinical merits against objective evidence, not the insurer’s cost calculations, and they regularly overturn denials that internal review upheld.

You can also file a complaint with your state’s Department of Insurance or explore ERISA-specific options for employer-sponsored plans.

Don’t give up after one “no.” The system is built around the assumption that you’ll stop after the first rejection. Persistence is part of the strategy.

Ozempic’s FDA-Approved Indications: Why They Matter for Your Appeal

Ozempic now carries more FDA-approved indications than most patients realize, and each one gives you a different angle in an appeal.

Type 2 diabetes (approved December 2017): For adults with type 2 diabetes as an adjunct to diet and exercise. The SUSTAIN trial program enrolled over 8,000 patients and demonstrated A1C reductions of 1.0% to 1.8% depending on dose.

Cardiovascular risk reduction (approved 2020): For adults with type 2 diabetes and established cardiovascular disease, to reduce the risk of heart attack, stroke, and cardiovascular death. SUSTAIN 6 showed a 26% reduction in major adverse cardiovascular events. No other step therapy alternative carries this indication.

Chronic kidney disease (approved January 2025): For adults with type 2 diabetes and CKD, to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death. The FLOW trial demonstrated a 24% risk reduction across 3,533 participants. It was the first and only GLP-1 approved for kidney outcomes.

Oral formulation (approved February 2026, available May 2026): Ozempic tablets (1.5 mg, 4 mg, and 9 mg) for adults with type 2 diabetes, providing an alternative to the injection. The tablets reformulate and replace what was previously marketed as Rybelsus. If your injectable Ozempic was denied, the oral formulation may have different formulary placement or coverage criteria worth exploring.

If your plan requires step therapy through metformin or other oral agents, the cardiovascular and kidney indications are your strongest leverage. None of those alternatives carry proven cardiovascular or renal outcomes data, which gives your prescriber a clear clinical basis for a step therapy exception.

How Long Does an Ozempic Appeal Take?

Typical timelines for each stage of an Ozempic insurance appeal.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	45–60 days
Full process (internal + external)	6–10 weeks

The single biggest factor in speed is completeness. Appeals with all documentation included move faster than submissions that trigger additional information requests. In some cases, Claimable submits appeals to both internal and external review simultaneously to compress the timeline.

An Easier Path: Let Claimable Handle Your Appeal

If navigating this process feels overwhelming, or if you’ve already been through a round of denials, Claimable can help.

All you have to do is answer a few questions about your denial and medical history, and we build a fully customized appeal using our work across millions of clinical studies, insurer policies, and legal standards. We submit directly to your insurer and guide you through escalation if needed.

Thousands of GLP-1 appeals have taught us how each major insurer and PBM operates. We know which arguments work, which escalation paths are effective, and where the pressure points are.

Appealing with Claimable is $39.95 for Ozempic. No success fees, no hidden costs. For a medication that runs $900 to $1,100 per month without coverage, it’s the difference between staying on a treatment that’s working and being forced off it because the system made fighting back too complicated.

Start your Ozempic appeal →

FAQs

Can I file my own appeal, or does my doctor handle that? You can and should file your own. Patient-initiated appeals run on a separate track from provider appeals, with their own legal protections, mandated timelines, and escalation rights. See Step 2 of the appeal guide above for how both tracks work together.

What’s the difference between Ozempic and Wegovy, and can I use Ozempic for weight loss? Same molecule (semaglutide), different FDA approvals. Ozempic is approved for type 2 diabetes, cardiovascular risk reduction, and kidney disease progression in adults with type 2 diabetes. Wegovy is approved for chronic weight management and cardiovascular risk reduction. Ozempic is not FDA-approved for weight loss, and insurers will almost universally deny coverage for that off-label use. If you are seeking semaglutide for weight management, Wegovy is the labeled product, and insurance coverage comes down to which diagnosis code is submitted.

Does Medicare cover Ozempic? Medicare Part D covers Ozempic for type 2 diabetes, though prior authorization is typically required. The Inflation Reduction Act’s $2,100 annual out-of-pocket cap for 2026 provides meaningful cost protection. Medicare does not cover Ozempic for weight loss. Starting July 1, 2026, a separate Medicare GLP-1 Bridge program will cover Wegovy, Zepbound (KwikPen), and Foundayo for weight management at a $50 monthly copay, but Ozempic is not included in that program.

My insurer wants me to try metformin first. Is that fair? Metformin is first-line therapy under ADA Standards of Care, and most insurers reasonably require a trial before approving a GLP-1. If metformin is contraindicated (kidney impairment is a common reason), caused intolerable side effects, or failed to achieve adequate glycemic control, those outcomes all count as “failure” under step therapy rules and support a step therapy exception.

What if my insurer prefers a different GLP-1? Your appeal should explain why Ozempic is specifically the right choice, focusing on its FDA-approved indications for cardiovascular and kidney outcomes, your established clinical response if you’re already on it, or contraindications to the preferred alternative.

How much does Ozempic cost without insurance? The list price is approximately $935 per month, with retail prices ranging from $800 to $1,100. If you need to bridge costs while appealing, Novo Nordisk’s NovoCare Pharmacy offers self-pay pricing of $349 to $499 per month depending on dose, with an introductory rate of $199 per month for new patients on starting doses (available through mid-2026). Commercially insured patients whose plans cover Ozempic can use the Ozempic Savings Card to reduce copays to as little as $25 per month. Low-income uninsured patients may qualify for free medication through Novo Nordisk’s Patient Assistance Program.

Is it worth appealing? In almost every case, yes. Fewer than 1% of denials are ever challenged, and the insurance industry’s entire denial infrastructure is calibrated around that silence. When patients do appeal with solid documentation, overturn rates are dramatically higher. If your doctor prescribed Ozempic, there’s a clinical reason, and an appeal puts that reasoning in front of someone required to evaluate it on the merits.

Claimable’s physician-led team has recovered over $30 million in care value for patients facing insurance denials. We’re SOC 2 Type II certified and HIPAA compliant. Learn more about how we work →

GLP-1

Type 2 Diabetes

June 18, 2026

Education

Min read

Insurance Won't Cover Mounjaro? Here's What to Do

Did your insurance deny coverage for Mounjaro? Here's why it was denied and how to fight back with an appeal that actually wins.

Mounjaro is the only dual GIP/GLP-1 available for type 2 diabetes, and your doctor prescribed it for a reason. When your insurer sends back a denial, it can feel like the end of the conversation. It isn’t.

Most commercial insurance plans and Medicare Part D formularies cover Mounjaro for type 2 diabetes, but “covered” doesn’t always mean to it's accessible. Prior authorization requirements, step therapy that tries to push you onto older medications first, and formulary restrictions (usually driven by rebate deals rather than clinical data) all create barriers between you and the prescription your doctor wrote. And if Mounjaro was prescribed off-label for weight loss, coverage can be an uphill battle. Because it's so complicated, many patients give up on treatment entirely after a denial rather than navigate the appeals process.

Less than 1% of denied claims get appealed, so the insurance industry assumes you’ll just accept their decision. That assumption saves insurers billions every year. But the low appeal rate says more about how opaque the process is than how unlikely you are to win. Patients who do push back with solid evidence see dramatically higher overturn rates. At Claimable, our appeals succeed over 80% of the time in established conditions.

The type of denial you received matters a lot in terms of how to write your appeal. A formulary restriction is different from a step therapy requirement, and this guide walks you through how to respond to each.

Why Listen to Us?

Claimable’s physician-led team has handled thousands of GLP-1 appeals. Our work draws on millions of clinical studies, insurer policies, and legal standards, built specifically to dismantle the arguments insurers use to block access to medications like Mounjaro. Insurers increasingly use AI and automation to deny claims in minutes. Claimable turns that same technology around and puts it to work for patients. We know which tactics each insurer relies on, and we know how to beat them.

Why Insurance Companies Deny Mounjaro Coverage

Before building your appeal, find the specific reason that your insurance denied coverage. Understanding your denial type means that you can fight it with the correct arguments.

What We See Across Thousands of GLP-1 Appeals

Denial letters use insurer language that's designed to sound final, even though most denials are anything but. Here’s how to decode the most common denial types for Mounjaro, what they actually say about your situation, and where to begin:

Common Mounjaro denial types, what the denial letter says, what it actually means, and the best first move for each.
Denial Type	What Your Letter Says	What It Actually Means	Best First Move
Off-Label Use / Not FDA-Approved	“Not indicated for weight loss” or “Not approved for this use”	Mounjaro was prescribed off-label for weight management, not type 2 diabetes	Discuss with your prescriber whether the prescription can be coded to an FDA-approved indication
Step Therapy Required	“Must try preferred alternatives first”	Insurer requires failure of cheaper diabetes medications before approving Mounjaro	Document why alternatives are clinically inappropriate, ineffective, or already tried
Not Medically Necessary	“Does not meet criteria for medical necessity”	Prior authorization submission lacked sufficient documentation	Strengthen documentation, get a letter of medical necessity
Not on Formulary / Non-Preferred	“Requested drug is non-preferred” or “Not on formulary”	Your plan prefers a different GLP-1 or diabetes medication	Request a formulary exception with clinical rationale
PA Requirements Not Met	“Does not meet prior authorization criteria”	Insurer applied criteria that your submission didn’t fully address	Review each criterion against your records and address gaps directly
Quantity Limit Exceeded	“Exceeds maximum quantity allowed”	Prescribed dose or supply exceeds your plan’s default limits	Request a quantity override with prescriber documentation

Off-Label Use Denials: The Weight Loss Problem

Mounjaro is FDA-approved only for type 2 diabetes. It isn't approved for weight loss, while Zepbound is – even though both contain tirzepatide. If Mounjaro is prescribed to a patient for weight loss, most insurers will deny coverage. That denial is hard to overturn because it’s technically correct.

Your options: If you have type 2 diabetes, the problem may be a coding issue rather than a real coverage dispute (see Step 0 below). If you don’t have diabetes and are seeking tirzepatide for weight management, consider asking your doctor about Zepbound, the version of tirzepatide that carries an FDA-approved weight management indication. If your prescriber believes off-label Mounjaro is clinically appropriate for a specific comorbidity, some plans will consider a formulary exception with a strong letter of medical necessity (though this is a harder fight).

Step Therapy Denials

Step therapy means that you have to fail cheaper medications before the insurer will approve Mounjaro. That usually means metformin first, and sometimes a second-line oral agent like a sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor. Some plans also require failure of a single-mechanism GLP-1 like semaglutide before approving a dual-mechanism one like Mounjaro.

The detail most patients miss: “failure” has a broad medical definition that works in your favor. Intolerable side effects, contraindications based on your medical history (even if you never took a dose), and inadequate glycemic control all qualify. If alternatives are clinically inappropriate, your doctor can request a step therapy exception. The SURPASS-2 trial, which demonstrated Mounjaro’s superiority over semaglutide at every dose, provides strong clinical rationale for why a “try semaglutide first” requirement may not serve your best interest.

Not Medically Necessary Denials

This denial rarely reflects a thorough clinical review. It usually means the PA submission lacked documentation, and it’s one of the most commonly overturned denial types on appeal.

What a strong submission requires: your current A1C, documented diabetes management history, comorbidities, prior medications tried and their outcomes, relevant lab work, and a clear rationale for why Mounjaro’s dual GIP/GLP-1 mechanism is clinically appropriate for your situation. If your initial submission was thin, a resubmission with thorough documentation can change the outcome entirely.

Not on Formulary / Non-Preferred Denials

This is more common with Mounjaro than with older GLP-1s. Many plans drug lists prefer semaglutide products because of pricing negotiations, regardless of the head-to-head clinical data that favors tirzepatide.

How to respond: Request a formulary exception. Every insurer is required to have one for non-formulary drugs that are medically necessary. Your case is strongest if formulary alternatives have failed, caused side effects, or are contraindicated. If you’ve already been responding well on Mounjaro, continuity of care is a powerful argument.

PA Requirements Not Met

This means the insurer says you didn’t satisfy one or more specific criteria, such as an A1C threshold, documented metformin use, or comorbidity documentation. Insurers sometimes misapply their own rules or overlook submitted documentation. Review each criterion against your records and address gaps directly in your appeal.

Quantity Limit Denials

How to Appeal a Mounjaro Denial: Step by Step

The initial denial is a starting point, not a verdict. Appeals exist because first-pass coverage decisions get it wrong all the time.

Step 0: Confirm Your Prescription is Coded Correctly

Before launching a formal appeal, rule out a coding error. A surprising number of Mounjaro denials trace back to a mismatch between the diagnosis code on the prescription and the drug’s FDA-approved indication.

If your prescriber submitted a vague code instead of a specific type 2 diabetes code (E11 and its subcategories), or if the prescription was flagged as weight management, the claim may have been auto-rejected without anyone reviewing your clinical history.

Getting the code corrected and resubmitting the prior authorization can resolve the issue.

Step 1: Read Your Denial Letter Carefully

Your denial letter is required by law to include the specific reason for denial, your appeal rights, and the deadline to file.

Step 2: Understand That You Have Your Own Appeal Rights

Your provider can appeal on the clinical side. But you also have the right to file your own appeal as the patient, and it runs on a separate track with its own legal protections.

Why this matters: Patient-initiated appeals carry guaranteed response timelines, external review rights, and multiple appeal levels that provider-level appeals may not offer.

Step 3: Get a Letter of Medical Necessity

A letter of medical necessity (LOMN) from your prescribing physician is an important document in your appeal package.

What a strong LOMN for Mounjaro should include: your diagnosis codes (E11.x for type 2 diabetes, plus relevant comorbidity codes), current and historical A1C levels, documented comorbidities, a summary of prior treatments tried and why each was insufficient or inappropriate, supporting clinical evidence from the SURPASS trials (particularly SURPASS-2 if the insurer is pushing a semaglutide alternative), and a clear explanation of why Mounjaro’s dual GIP/GLP-1 mechanism is the clinically appropriate choice for your situation.

How to ask: Be direct with your doctor. “My insurance denied Mounjaro. Would you be willing to write a letter of medical necessity for my appeal? I can provide information on what the insurer typically looks for.” If your doctor’s office hasn’t written many of these, offering to share a template can improve the quality and completeness of the letter. You can download our LOMN template here and forward it to your provider.

Step 4: Build Your Appeal Package

Your submission should include a cover letter summarizing your case, the letter of medical necessity, supporting clinical documentation (A1C history, lab results, visit notes, weight and metabolic data), and a personal statement explaining how the denial has affected your health and daily life.

A winning appeal weaves together three elements:

Your story: The real-world impact of being denied this medication, and how it affects your ability to manage your health, work, and daily life. The person reviewing your appeal is a human being, and personal context shifts how they read the clinical data.

Clinical evidence: A1C reductions of up to 2.07% in SURPASS-1, superiority over semaglutide across all doses in SURPASS-2, and up to 92% of participants reaching the ADA’s target A1C using the efficacy estimand. Tailor the evidence to your specific clinical situation.

Policy and legal analysis: How your case satisfies your plan’s own coverage criteria, applicable state insurance laws, and federal protections under the ACA. If the denial contradicts the insurer’s published medical policy, name the contradiction explicitly.

Step 5: Submit and Track

Submit to your insurer per the instructions in your denial letter. They’re required to respond within 30 days for standard appeals (72 hours for urgent appeals).

Keep records: Save confirmation numbers, note submission dates and methods (fax, mail, portal), and write down the name of every person you speak with. Documents go missing in insurer systems more often than you’d expect, and a clear paper trail is your best protection.

Step 6: Escalate If Needed

If your internal appeal is denied, that’s still not the end. You have the right to an external review conducted by an independent third party with no ties to the insurer. External reviewers assess the clinical evidence on its own terms, not through the lens of the insurer’s cost structure, and they overturn internal denials regularly.

State Department of Insurance complaints and ERISA-specific remedies for employer-sponsored plans are additional escalation paths.

Don’t give up after one “no.” The entire system is built around the assumption that you’ll stop after the first rejection. Be persistent.

Mounjaro’s FDA-Approved Indications: Why They Matter for Your Appeal

Mounjaro’s clinical profile is narrower than some other GLP-1s in terms of FDA-approved indications, but its efficacy data within those indications is among the strongest available.

Type 2 diabetes in adults (approved May 2022): As the first and only dual GIP/GLP-1 receptor agonist, Mounjaro was approved based on the SURPASS trial program. SURPASS-1 demonstrated A1C reductions of up to 2.07% as monotherapy. SURPASS-2 showed superiority over semaglutide 1 mg at all three doses. Using the efficacy estimand, A1C reductions reached up to 2.46% versus 1.86% for semaglutide, and up to 92% of participants reached the ADA’s target A1C of less than 7%. Using the treatment-regimen estimand, A1C reductions reached up to 2.30% versus 1.86%, with up to 86% reaching target.

Type 2 diabetes in pediatric patients (approved December 2025): Expanded to include patients 10 years of age and older with type 2 diabetes inadequately controlled with metformin, basal insulin, or both. The pediatric indication covers the 5 mg and 10 mg doses only, based on the SURPASS-PEDS trial results; the 15 mg dose was not studied in pediatric patients.

Unlike Ozempic, Mounjaro does not currently carry separate FDA-approved indications for cardiovascular risk reduction or chronic kidney disease. This means appeals that rely on cardiovascular or renal arguments need to reference the clinical literature rather than an on-label indication. That said, Mounjaro’s superior head-to-head data against semaglutide for glycemic control remains a powerful differentiator when insurers try to substitute a less effective alternative.

How Long Does a Mounjaro Appeal Take?

Typical timelines for each stage of a Mounjaro insurance appeal.
Appeal Stage	Typical Timeline
Internal appeal (standard)	Up to 30 days
Internal appeal (urgent/expedited)	72 hours
External review	45–60 days
Full process (internal + external)	6–10 weeks

Complete submissions help your appeal move faster. In some cases, Claimable submits appeals to both internal and external review simultaneously to compress the timeline.

The Easier Path: Let Claimable Handle Your Appeal

If you’d rather not navigate this process alone, Claimable can help.

Here’s how it works: You provide a few details about your denial and medical history, and we generate a fully customized appeal backed by our work across millions of clinical studies, insurer policies, and legal standards. We fax and mail it for you, so no trips to the post office or hassle to print.

We’ve handled thousands of GLP-1 cases, so we know which arguments work with which insurers, what to escalate and when, and we’re here to help you through any questions you may have.

Appealing with Claimable costs $39.95 (plus shipping) for a Mounjaro appeal, with no success fees or hidden charges. When the medication itself runs over $1,000 a month without coverage, that’s a small price to keep a treatment that’s working.

Start your Mounjaro appeal →

FAQs

Can I file my own appeal, or does my doctor handle that? Both. Your provider appeals on the clinical side, but you have a separate right to appeal as the patient, with its own legal protections and mandated response timelines. Running both tracks simultaneously gives you the best chance of getting the denial reversed. See Step 2 above.

What’s the difference between Mounjaro and Zepbound? Same molecule (tirzepatide), different FDA approvals. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management and obstructive sleep apnea. If you are seeking tirzepatide for weight management and don’t have type 2 diabetes, Zepbound is the labeled product. Insurance coverage comes down to which diagnosis code is submitted.

Does Medicare cover Mounjaro? Medicare Part D covers Mounjaro for type 2 diabetes, though prior authorization is typically required. The Inflation Reduction Act’s $2,100 annual out-of-pocket cap for 2026 provides meaningful cost protection. Medicare does not cover Mounjaro for weight loss.

My insurer wants me to try a different GLP-1 first. What’s the argument against that? SURPASS-2 directly compared tirzepatide to semaglutide and found tirzepatide delivered superior A1C reductions at every dose. If your insurer is requiring you to try semaglutide before approving Mounjaro, that step therapy requirement asks you to use a medication that performed less effectively in the head-to-head data. Your prescriber can cite SURPASS-2 in a step therapy exception request.

How much does Mounjaro cost without insurance? The list price is approximately $1,080 per month. If you have commercial insurance and a type 2 diabetes diagnosis, the Mounjaro Savings Card can reduce your copay to as little as $25 per month, or up to roughly $499 per month if your commercial plan doesn’t cover the medication. For self-pay patients, Mounjaro is now available through LillyDirect at around $299 per month for any dose. Government insurance beneficiaries (Medicare, Medicaid, TRICARE) are not eligible for the savings card but may qualify for assistance through the Lilly Cares Foundation.

Is it worth appealing? Almost always. The insurance industry’s denial system is calibrated around the fact that virtually nobody challenges them. When patients do file appeals with complete documentation, the results are far better than the initial denial would suggest. Your doctor prescribed Mounjaro for a reason, and an appeal forces someone to evaluate that clinical reasoning on its merits rather than rejecting it on a technicality.

Claimable has recovered over $30 million in care value for patients. Our platform is SOC 2 Type II certified and HIPAA compliant, and our appeals are reviewed by licensed physicians. Learn more about how we work →

GLP-1

Type 2 Diabetes